MeiraGTx Hldgs

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Crude Oil and Petroleum Trade in the Crosshairs

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ADTX

AVAH

CNTY

LFWD

MGTX

PATH

Crude Oil Falls 1%; Dollar General Posts Upbeat Sales

Movers_Stocks

Movers

ALGM

BLDP

CMTG

DLTR

GIII

INTC

LEGH

PHAR

QBTS

G-III Apparel Posts Better-Than-Expected Earnings, Joins Ballard Power Systems, Dollar General And Other Big Stocks Moving Higher On Thursday

Elevate,Healthcare,With,Ai,Technology,Services.virtual,Health,Care,Analytics,Empower

Biotech

Health Care

Contracts

General

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson&#39;s and CNS treatments.

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson&#39;s Candidate, Stock Soars

MeiraGTx Holdings PLC

Press Releases

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

LIAN

OLMA

TLPH

Akebia Therapeutics

AnaptysBio

ArriVent BioPharma

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Kura Oncology

LENZ Therapeutics

Organogenesis Holdings

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Relay Therapeutics

Sage Therapeutics

Sionna Therapeutics

Savara

Tyra Biosciences

Valneva

Verve Therapeutics

RBC Capital

Chardan Capital

Piper Sandler

Barclays

Comments

MeiraGTx Hldgs

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga